About: Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $97.10 (-1.11%)
INBX NASDAQ Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. share price
Atividade de preço de INBX
Último preço
$ 97,100
Variação (24h)
-1,09 USD (1,11%)
Volume
249.50K
Volume (média 4 sem.)
-
Abertura
$ 95,65
Variação do dia
$ 94,04 - $ 100,20
Fechamento anterior
$ 98,19
Último negócio
22 Oct, 8:00 pm GMT+0
Atrasado
22 Oct, 8:00 pm GMT+0
INBX price performance
Atrasado
22 Oct, 8:00 pm GMT+0
quote.marketSignals